Medtronic Q3 FY26 revenue rises 8.7% to $9.0 billion; reiterates full-year guidance
Medtronic reported fiscal third-quarter 2026 revenue of $9.017 billion, up 8.7% as reported and 6.0% organic, but GAAP diluted EPS fell to $0.89 from $1.01 a year earlier and non-GAAP diluted EPS fell to $1.36 from $1.39. The company reiterated its FY26 organic revenue growth of about 5.5% and non-GAAP diluted EPS guidance of $5.62 to $5.66, so shareholders see sales growth alongside lower profit per share in the quarter.
Key points
- Q3 revenue of $9.017 billion, up 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidance
- GAAP diluted EPS of $0.89 vs. $1.01 a year earlier; non-GAAP diluted EPS of $1.36 vs. $1.39
- Cardiovascular Portfolio revenue of $3.457 billion, up 13.8%; Cardiac Ablation Solutions revenue up 80%
- FY26 guidance reiterated: organic revenue growth of about 5.5% and non-GAAP diluted EPS of $5.62 to $5.66, including a potential tariff impact of about $185 million
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 17, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.